We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from our medicines. Our pipeline includes the advanced Phase 2 lead program, ACR-368 (prexasertib), a clinically active CHK1/2 inhibitor andco-crystallography-driven, internally developed pipeline programs, consisting of its clinical candidate, ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor, and a preclinical cell cycle program with an undisclosed target.